Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
about
Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.MiR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis.Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomesBiological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
P2860
Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@ast
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@en
type
label
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@ast
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@en
prefLabel
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@ast
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@en
P2093
P2860
P1476
Xanthatin, a novel potent inhi ...... growth in breast cancer cells.
@en
P2093
Chong Gang Pei
Gui Ping Gao
Yun Yan Li
P2860
P304
10355-10364
P577
2015-09-01T00:00:00Z